- It is important to note the high probability that the comorbidities in 97.5 % of patients could have contributed to the deaths of the patients.
- Small sample size of 77 patients 

Santa Clara University

- 77 patients with SARS_CoV-2 were investigated between march 1 and April 30, 2020 at the “Casa Sollievo della Sofferenza” Research Hospital. 

Details of a study investigating the relationship between ADAMTS13 levels and COVID-19 mortality

- Tiscia, G. L., Favuzzi, G., De Laurenzo, A., Cappucci, F., Fischetti, L., di Mauro, L., Miscio, G., Mirijello, A., Chinni, E., Grandone, E., & CSS COVID-19 Group (2020). Reduction of ADAMTS13 Levels Predicts Mortality in SARS-CoV-2 Patients. TH open : companion journal to thrombosis and haemostasis, 4(3), e203–e206. https://doi.org/10.1055/s-0040-1716379

Reduction of ADAMTS13 Levels Predicts Mortality in SARS-CoV-2 Patients. 

- ADAMTS13 levels, vWF antigen (the substrate of ADAMTS13) and natural anticoagulants (AT, PC, and PS) levels in the blood were measured in each of the 77 patients within seven days of admission to the hospital. 

Dependent Variables of the Investigation Between ADAMTS13 Levels and Covid-19 mortality

- 97.5% of patients had comorbidities 
- 73% of patients were older than 60 years. 


Comorbidity Details of Patients Involved in the Investigation Between ADAMTS13 Levels and COVID-19 mortality

- The median value of ADAMTS13 activity median value was 70 U/dL.
- The kaplan-meier analysis demonstrated that a significantly lower survival rate was seen in patients who had lower ADAMTS13 activity than the median value of 70 U/dL.  
- vWF antigen levels did not appear to be associated with risk of death from SARS-CoV-2 infection. 


Learn Before

Related